



Not for release to US wire services or distribution in the United States

17 August 2023

Dear shareholder

Notice regarding Actinogen's \$10 million non-renounceable rights offer

On Wednesday 2 August, **Actinogen Medical Limited (Actinogen)** announced to the Australian Securities Exchange (**ASX**) a non-renounceable pro-rata rights issue offer (**Rights Issue Offer**) to eligible shareholders to:

- acquire **1 New Share for every 4.54 Shares** held by shareholders at the Record Date (14 August 2023) at an issue price of 2.5 cents (\$0.025) per New Share (**Entitlement**),
- receive for no additional payment **1 New Option** with an exercise price of 3.75 cents (\$0.0375) and an expiry date 36 months from the date of issue for every 2 New Shares issued to you under the Rights Issue Offer, and
- have the ability to apply for Additional Shares (and corresponding New Options) (**Top Up Offer**) if you subscribe for your full pro rata Entitlement initially,

(together, the **Offers**) to raise a maximum of approximately \$10 million (before costs). The Directors have also reserved the right to place any Shortfall (being the aggregate amount, if any, for which eligible shareholders do not subscribe under the Offers), and corresponding New Options, to qualifying investors for a period of 3 months after the Close of the Offer.

A Prospectus in relation to the Offers was lodged with the ASX and ASIC on Tuesday 8 August 2023 and is available to view on Actinogen's website at <https://actinogen.com.au>, as well as the ASX website. All other announcements in relation to the Offer are also available on the Actinogen and ASX websites.

Details of how to obtain a copy of the Prospectus, together with your personalised entitlement and acceptance form, appear in the table below. Shareholders with registered addresses outside Australia and New Zealand are not eligible to participate in the Offer unless certain exemptions apply, as detailed in the Prospectus.¹

Actinogen will **not** be printing / dispatching hard copies of the Prospectus or Application Forms, except in response to a specific request by a Shareholder (please refer below).

Instead, an electronic copy of the Prospectus and your personalised Application Form is accessible by you (using your Securityholder Reference Number (SRN) or Holder Identification Number (HIN) from your latest Holding Statement (and your postcode) at the following link:
<https://investor.automic.com.au>

¹ If in Singapore or the United Kingdom, the Shareholder must be an Institutional Investor. If in the United States, the Shareholder must be an employee of the Company.

Shareholders should read the Prospectus in full prior to making an application under the Offers. Your application under the Offers must be completed by making payment in accordance with the personalised payment instructions on your Application Form and in the Prospectus. Your acceptance of the Offers should be made using this online service.

To download your Application Form, you have the following three choices:

I already have an online account with the Automic Share registry	I don't have an online account with Automic – but wish to register for one	I don't have an online account with Automic – but want to use Automic for this Offer only
https://investor.automic.com.au Select: "Existing Users Sign In" Once you have successfully signed in, click on "Documents and Statements" Download the Prospectus and Application Form	https://investor.automic.com.au/#/signup Select: Actinogen Medical Limited from the dropdown list in the ISSUER field. Enter you holder number SRN / HIN (from your latest Holding Statement) Enter Postcode (Aust only) or Country of Residence (if not Australia) Tick box "I am not a robot", then Next. Complete prompts Once you have successfully signed in, click on "Documents and Statements" Download the Prospectus and Application Form	https://investor.automic.com.au/#/loginsah Select: Actinogen Medical Limited from the dropdown list in the ISSUER field Enter you holder number SRN / HIN (from your latest Holding Statement) Enter Postcode (Aust only) or Country of Residence (if not Australia) Tick box "I am not a robot", then Access Once you have successfully signed in, click on "Documents and Statements" Download the Prospectus and Application Form

If you are unable to access <https://investor.automic.com.au> online, you can obtain a copy of the Prospectus and your Application Form – initially by calling Automic Group on 1300 288 664 or emailing hello@automicgroup.com.au and asking them to mail a paper copy of the Prospectus and your Application Form to you free of charge. After your request has been acknowledged by Automic you will need to provide your SRN or HIN and postcode to complete this request.

To accept an Offer using these paper copy documents, you will still need to make payment via BPay® or via Electronic Funds Transfer (EFT). For shareholders unable to make payment via Bpay, please follow the instructions on the Application form to make payment via Electronic Funds Transfer (EFT).

The Offer closes at 7:00 pm (AEST) on Monday 4 September 2023.

The current timetable for the Offer is as follows:

Event	Date
Announcement of Offer	Wednesday 2 August 2023
Prospectus lodged with ASX and ASIC and announced to ASX	Tuesday 8 August 2023
Shares commence quotation on an 'ex' basis ('ex' date)	Friday 11 August 2023
Record Date to determine entitlements under Offer	Monday 14 August 2023
Entitlement and Acceptance Forms despatched to Eligible Shareholders and announced to the ASX	Thursday, 17 August 2023
Offer opens	Thursday 17 August 2023
Offer closes	7.00pm (AEST) Monday 4 September 2023
Shares commence quotation on a deferred settlement basis	Tuesday 5 September 2023
ASX notified of results of Offer and of any under-subscriptions (i.e. shortfall)	Thursday 7 September 2023
Allotment and issue of New Shares and New Options under Offer	Monday 11 September 2023
Deferred settlement trading ends	Monday 11 September 2023
Expected normal trading of New Shares commences	Tuesday 12 September 2023

These dates are indicative only and subject to change. Actinogen reserves the right, subject to the Corporations Act and the ASX Listing Rules, to change any date including to extend the closing date of the Offer, to close the Offer early, to accept late acceptances either generally or in particular cases, or to withdraw or reduce the size of the Offer without notice. Any extension of the closing date will have a consequential effect on the issue date of new shares.

Funds raised from the Offer (after payment of expenses in connection with the Offer) will be used to progress the Company's Phase 2 clinical trial program including completion of the XanaCIDD trial in patients with cognitive impairment associated with depression, startup activities for the XanaMIA trial in patients with mild-moderate Alzheimer's disease, and general working capital purposes.

If you have any questions about the Offer, please contact:

- Peter Webse, Actinogen's company secretary at pwebse@governancecorp.com.au, or
- Michael Roberts Actinogen's Head of Investor Relations at michael.roberts@actinogen.com.au.

For any other registry related matters, contact Actinogen's share registrar, Automic Registry Services as follows:

Email: hello@automicgroup.com.au

Address: Level 5/126 Phillip St, Sydney NSW 2000

Phone: **1300 288 664 (within Australia)**, or **+61 2 9698 5414 (international)** between 8:30 am and 5:00 pm (AEST) Monday to Friday.

Yours faithfully



Peter Webse
Company Secretary

This letter has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This letter does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this letter have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.